Epocrates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$35.0m | Series B | ||
N/A | Series C | ||
N/A | Seed | ||
N/A | N/A | IPO | |
N/A | Acquisition | ||
Total Funding | €31.8m |
Related Content
Recent News about Epocrates
EditEpocrates operates in the healthcare technology market, providing a comprehensive medical reference app primarily for healthcare providers. The app offers a wide range of features including drug information, interaction checks, pill identification, clinical practice guidelines, and formulary data. It serves a diverse client base of over one million healthcare professionals, including physicians, pharmacists, and nurses. The business model is subscription-based, with users paying either an annual fee of $174.99 or a monthly fee of $16.99 to access premium content such as robust disease and alternative medicine information, labs, and diagnostic data. Epocrates generates revenue through these subscriptions, offering essential clinical decision support that saves time and enhances the quality of care. The company’s content is curated by a dedicated team of pharmacists, physicians, and associates to ensure it is objective, accurate, current, concise, and clinically relevant.
Keywords: medical reference, healthcare providers, drug information, interaction checks, clinical guidelines, pill identification, formulary data, subscription model, clinical decision support, healthcare technology.